About Us
Mission
Our History
People
R&D
Angiogenesis
Pathological Angiogenesis
Anti-Angiogenic Therapy
Synthetic Peptides
Pipeline
Therapeutic Agents
Licensing
National Patents
International Patents
Licensing-out/partnership
Publications
ANBITION Publications
Related Publications
Collaborations
Contact us
Oral Delivery of a Tetrameric Tripeptide Inhibitor of VEGFR1 Suppresses Pathological Choroid Neovascularization
Go
Oral Delivery of a Tetrameric Tripeptide Inhibitor of VEGFR1 Suppresses Pathological Choroid Neovascularization
Gen 16,2020
Leave a comment
By wp_3476655
Tarallo V. et al,
International Journal of Molecular Sciences
21:410 (2020)
Comments are closed
News list
VEGFR1 signaling in retinal angiogenesis and microinflammation.
Maggio 13, 2021
Three new ANBITION patents filed on November 30th, 2020
Gennaio 1, 2021
Oral Delivery of a Tetrameric Tripeptide Inhibitor of VEGFR1 Suppresses Pathological Choroid Neovascularization
Gennaio 16, 2020
ANBITION collaborates to publish data on retinal inflammation elicited by high glucose
Settembre 16, 2019
ANBITION web site is on line
Dicembre 21, 2018
